| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (NCT04870944) | Children's Oncology Group | 2022-01-28 |
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors (NCT05071209) | National Cancer Institute (NCI) | 2021-12-22 |
| Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers (NCT04090619) | M.D. Anderson Cancer Center | 2021-06-22 |
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study (NCT04500548) | National Cancer Institute (NCI) | 2021-05-11 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04320888) | National Cancer Institute (NCI) | 2021-05-03 |
| Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (NCT03418038) | Mayo Clinic | 2018-03-23 |
| Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma (NCT03323034) | Children's Oncology Group | 2018-01-11 |
| IACS-010759 in Advanced Cancers (NCT03291938) | M.D. Anderson Cancer Center | 2017-11-13 |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma (NCT03229278) | Rutgers, The State University of New Jersey | 2017-10-03 |
| Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (NCT02780804) | National Cancer Institute (NCI) | 2017-01-06 |
| Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas (NCT02323880) | Children's Oncology Group | 2015-10-30 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours (NCT02343718) | Canadian Cancer Trials Group | 2015-06-24 |
| Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment (NCT01790152) | Children's Oncology Group | 2014-03-05 |